NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

US Preventive Services Task Force. Guide to Clinical Preventive Services: Periodic Updates [Internet]. 3rd edition. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002-.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Guide to Clinical Preventive Services

Guide to Clinical Preventive Services: Periodic Updates [Internet]. 3rd edition.

Show details


United States Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Alexandria, VA: Office of Disease Prevention and Health Promotion; 1996.
Harris R, Donahue K, Rathore S, Frame P, Woolf S, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;138:215–290. [PubMed: 12558362]
  • 3. Harris R, Lux L, Bunton A, et al. Screening for Type 2 Diabetes Mellitus: Systematic Evidence Review No. 19 (Prepared by Research Triangle Institute—University of North Carolina Evidence‐based Practice Center under Contract No. 290‐97‐0017). Rockville, MD. Agency for Healthcare Research and Quality. May 2002 (Available on the AHRQ Web site at: www​
  • 4.
    Harris MI, Flegal KM, Cowie CC. et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third National Health and Nutrition Examination Survey, 1988‐1994. Diabetes Care. 1998;21:518–524. [PubMed: 9571335]
    Boyle JP, Honeycutt AA, Narayan KM. et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24:1936–40. [PubMed: 11679460]
    Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology. 1988;95(10):1340–8. [PubMed: 3265775]
    Eastman RC, Javitt JC, Herman WH. et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1997;20(5):725–734. [PubMed: 9135934]
    Eastman RC, Javitt JC, Herman WH. et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost‐effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20(5):735–744. [PubMed: 9135935]
    Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non‐insulin‐dependent diabetes mellitus. A population‐based study in Rochester, Minnesota. Ann Intern Med. 1989;111(10):788–796. [PubMed: 2817626]
    Resnick HE, Valsania P, Phillips CL. Diabetes mellitus and nontraumatic lower extremity amputation in black and white Americans: The National Health and Nutrition Examination Survey Epidemiologic Follow‐up Study, 1971‐1992. Arch Intern Med. 1999;159:2470–275. [PubMed: 10665896]
    Humphrey LL, Palumbo PJ, Butters MA. et al. The contribution of non‐insulin‐dependent diabetes to lower‐extremity amputation in the community. Arch Intern Med. 1994;154:885–892. [PubMed: 8154951]
    UK Prospective Diabetes Study Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998352(9131):837–853. [PubMed: 9742976]
    Moss SE, Klein R, Klein BE. The 14‐year incidence of lower‐extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1999;22(6):951–959. [PubMed: 10372248]
    American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997 Diabetes Care 199821296–309. [PubMed: 9539999]
    McCance DR, Hanson RL, Charles MA. et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308(6940):1323–1328. [PMC free article: PMC2540244] [PubMed: 8019217]
    Engelgau MM, Thompson TJ, Herman WH. et al. Comparison of fasting and 2‐hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care. 1997;20:785–791. [PubMed: 9135943]
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 1997201183–1197. [PubMed: 9203460]
    Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 sudies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240. [PubMed: 10333939]
    Engelgau MM, Thompson TJ, Smith PJ. et al. Screening for diabetes mellitus in adults. The utility of random capillary blood glucose measurements. Diabetes Care. 1995;18(4):463–466. [PubMed: 7497854]
    Harwell TS, Smilie JG, McDowall JM, Helgerson SD, Gohdes D. Diabetes screening practices among individuals aged 45 years and older. Diabetes Care. 2000;23(1):125–126. [PubMed: 10857982]
    Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002346393–403. [PMC free article: PMC1370926] [PubMed: 11832527]
    Tuomilehto J, Lindstrom J, Eriksson JG. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–5130. [PubMed: 11333990]
    Pan XR, Li GW, Hu YH. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544. [PubMed: 9096977]
    Ohkubo Y, Kishikawa H, Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Res Clin Pract. 1995;28:103–117. [PubMed: 7587918]
    UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 6: complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors Diabetes Res 1990131–11. [PubMed: 2097090]
    Kohner EM, Aldington SJ, Stratton IM. et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non‐insulin‐dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 1998;116(3):297–303. [PubMed: 9514482]
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 1998317703–713. [PMC free article: PMC28659] [PubMed: 9732337]
    Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta‐regression analysis. Ann Intern Med. 1993;118(2):129–138. [PubMed: 8416309]
    Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Systematic Review 2001;1:CD002183. [PubMed: 11279757]
    Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood‐pressure‐lowering agents: a meta‐analysis of comparative trials. Nephrol Dial Transplantation. 1995;10(11):1963–1974. [PubMed: 8643149]
    Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20(10):1576–1581. [PubMed: 9314638]
    Lewis EJ, Hunsicker LG, Clarke WR. et al. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860. [PubMed: 11565517]
    Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. [PubMed: 11565518]
    Parving HH, Lehnert H, Brochner‐Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878. [PubMed: 11565519]
    Ravid M, Brosh D, Levi Z, Bar‐Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128(12 Pt 1):982–988. [PubMed: 9625684]
    Fogari R, Zoppi A, Corradi L. et al. Long‐term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type 2 diabetes and impaired renal function. J Human Hyperten. 1999;13(1):47–53. [PubMed: 9928752]
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–153. [PubMed: 10639539]
    Mason J, O'Keeffe C, McIntosh A, Booth A, Young RJ. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus: prevention. Diabet Med. 1999;16:801–812. [PubMed: 10547206]
    Malone JM, Snyder M, Anderson G, Bernhard VM, Holloway GAJ, Bunt TJ. Prevention of amputation by diabetic education. Am J Surg. 1989;158:520–523. [PubMed: 2589581]
    Litzelman DK, Slemenda CW, Langefeld CD. et al. Reduction of lower extremity clinical abnormalities in patients with non‐insulin‐dependent diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1993;119:36–41. [PubMed: 8498761]
    Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762. [PubMed: 9635947]
    Curb JD, Pressel SL, Cutler JA. et al. Effect of diuretic‐based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886–1892. [PubMed: 8968014]
    Tuomilehto J, Rastenyte D, Birkenhager WH. et al. Effects of calcium‐channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340(9):677–684. [PubMed: 10053176]
    Tatti P, Pahor M, Byington RP. et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603. [PubMed: 9571349]
    Haffner SM, Alexander CM, Cook TJ. et al. Reduced coronary events in simvastatin‐treated patients with coronary heart disease and diabetes or impaired fasting glucose levels:subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661–2667. [PubMed: 10597756]
    The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 19983391349–1357. [PubMed: 9841303]
    Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high‐density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418. [PubMed: 10438259]
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial Lancet 2002360(9326):7–22. [PubMed: 12114036]
    Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the u.s. Preventive services task force. Ann Intern Med. 2002;136(2):161–72. [PubMed: 11790072]
    Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 1997;20:1767–71. [PubMed: 9353620]
    American Diabetes Association. Aspirin therapy in diabetes Diabetes Care 200023S61–S62. [PubMed: 12017681]
    Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabetes Care. 2002;25(6):1022–6. [PubMed: 12032109]
    Eriksson KE, Lindgarde F. Impaired glucose tolerance in a middle‐aged male urban population: a whole new approach for identifying high‐risk cases. Diabetologia. 1990;33:526–531. [PubMed: 2253828]
    Yudkin JS, Alberti KGMM, McLarty DG, Swai ABM. Impaired glucose tolerance: is it a risk factor for diabetes or a diagnostic ragbag? BMJ. 1990;301:397–401. [PMC free article: PMC1663662] [PubMed: 2282392]
    Balkau B, Eschwege E. Repeatability of the oral glucose tolerance test for the diagnosis of impaired glucose tolerance and diabetes mellitus. Diabetologia. 1991;34:201–202. [PubMed: 1884894]
    Ramaiya KL, Swai ABM, McLarty DG, Kitange HM, Alberti KGMM. Improvement in glucose tolerance after one year of follow‐up in a Hindu community in Africa. Diabet Res Clin Pract. 1990;10:245–255. [PubMed: 2073872]
    Swai ABM, McLarty DG, Kitange HM. et al. Study in Tanzania of impaired glucose tolerance: methodological myth? Diabetes. 1991;40:516–520. [PubMed: 2010053]
    Bourn DM, Williams SM, Mann JI. Distinguishing between persistent and transient impaired glucose tolerance using a prediction model. Diabet Med. 1992;9:744–748. [PubMed: 1395468]
    Warram JH, Sigal RJ, Martin BC, Krolewski AS, Soeldner JS. Natural history of impaired glucose tolerance: follow‐up at Joslin Clinic. Diabet Med. 1996;13:S40–S45. [PubMed: 8894480]
    Israili ZH, Wall WD. Cough and angioneurotic edema associated with angiotensin‐coverting‐enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234–242. [PubMed: 1616218]
    Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin‐gemfibrozil combination therapy. JAMA. 1990;264:71–75. [PubMed: 2355431]
    Bradford RH, Shear CL, Chremos AN. et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two‐year efficacy and safety follow‐up. Am J Cardiol. 1994;74:667–73. [PubMed: 7942524]
    Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Diabetes Care. 1998;21 Suppl 3:C44–52. [PubMed: 9850489]
    Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double‐blind trial. JAMA. 1998;280:1490–1496. [PubMed: 9809729]
    UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37) Diabetes Care 1999221125–1136. [PubMed: 10388978]
    Screening for Diabetes. Diabetes Care American Diabetes Association 200225(90001)S21–S24.
    American College of Obstetricians and Gynecologists. Guidelines for Women's Health Care. 2nd Edition. Washington DC; American Coll of Obstetricians and Gynecologists; 2002:210‐213.
    Pearson TA, Blair SN, Daniels SR. et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388–91. [PubMed: 12119259]


    • PubReader
    • Print View
    • Cite this Page

    Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...